LATAM Tuberculosis Testing Market Size & Outlook, 2025-2033
LATAM Tuberculosis Testing Market Insights
- As highlighted in Reed Intelligence analysis, the LATAM Tuberculosis Testing Market, valued at USD 103.29 Million in 2024, is estimated to achieve USD 164.4 Million by 2033.
- The market is estimated to grow at a CAGR of 5.32% spanning 2026 to 2033.
- By market size, Radiographic Test led the By Diagnostic Test Type category in 2024.
- The By Diagnostic Test Type segment led by Other Diagnostic Test Types is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- LATAM represented 5.27% of the global Tuberculosis Testing Market size in 2024.
- By 2033, United States is estimated to hold the largest position in the global market in terms of size.
- Mexico is estimated to remain the fastest-growing market in LATAM, advancing to USD 60.55 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 103.29 Million |
| Market Size In 2033 | USD 164.4 Million |
| Largest segment | Radiographic Test |
| Units | Revenue in USD Million |
| CAGR | 5.32% (2025-2033) |
| Segmnetation Covered | |
| LATAM |
|
| By Diagnostic Test Type |
|
| By End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
LATAM Tuberculosis Testing Market Country 2025-2033 (USD Million)
| LATAM | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil | XX.x | XX.x | XX.x | 39.32 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Mexico | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Argentina | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Colombia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Chile | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
LATAM Tuberculosis Testing Market By Diagnostic Test Type 2025-2033 (USD Million)
| By Diagnostic Test Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radiographic Test | XX.x | XX.x | XX.x | 29.01 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Smear Microscopy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Culture-Based Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nucleic Acid Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cytokine Detection Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Drug Resistance Test | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Diagnostic Test Types | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
LATAM Tuberculosis Testing Market By End User 2025-2033 (USD Million)
| By End User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital/Clinic | XX.x | XX.x | XX.x | 65.13 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostics/Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
